No retraction, correction or concern found when last checked on Nov 4, 2026.
Fragment binding to the Nsp3 macrodomain of SARS-CoV-2 identified through crystallographic screening and computational docking
Marion Schuller, Galen J. Correy, Stefan Gahbauer and 51 more
Science Advances · 2021
Abstract
Massive fragment screening effort provides a foundation for the development of macrodomain inhibitors as novel antiviral agents.
Cited by papers we hold 6
- Structure-based drug design with equivariant diffusion models · 2024No notice
- Iterative computational design and crystallographic screening identifies potent inhibitors targeting the Nsp3 macrodomain of SARS-CoV-2 · 2023No notice
- Ultralarge Virtual Screening Identifies SARS-CoV-2 Main Protease Inhibitors with Broad-Spectrum Activity against Coronaviruses · 2022No notice
- Structural biology of SARS-CoV-2: open the door for novel therapies · 2022No notice
- Current status of structure-based drug repurposing against COVID-19 by targeting SARS-CoV-2 proteins · 2021Not checked
- Structure, mechanism and crystallographic fragment screening of the SARS-CoV-2 NSP13 helicase · 2021No notice
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.